Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 6.6% in March

Cellectis S.A. (NASDAQ:CLLSGet Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 679,300 shares, a decrease of 6.6% from the February 29th total of 727,500 shares. Based on an average daily trading volume, of 50,500 shares, the short-interest ratio is presently 13.5 days.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CLLS. Oppenheimer & Co. Inc. increased its position in Cellectis by 9.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 133,143 shares of the biotechnology company’s stock worth $410,000 after purchasing an additional 11,723 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Cellectis by 44.4% during the 4th quarter. BNP Paribas Financial Markets now owns 15,800 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 4,856 shares in the last quarter. LPL Financial LLC lifted its position in Cellectis by 354.5% during the 3rd quarter. LPL Financial LLC now owns 63,657 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 49,650 shares in the last quarter. CVI Holdings LLC purchased a new stake in Cellectis during the 1st quarter worth approximately $250,000. Finally, OLD Mission Capital LLC increased its holdings in shares of Cellectis by 90.0% in the 1st quarter. OLD Mission Capital LLC now owns 22,329 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 10,577 shares during the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Stock Performance

Shares of NASDAQ CLLS traded up $0.12 during mid-day trading on Tuesday, hitting $2.66. 33,457 shares of the company were exchanged, compared to its average volume of 42,434. The company has a quick ratio of 2.20, a current ratio of 2.20 and a debt-to-equity ratio of 0.57. The stock has a 50 day simple moving average of $2.73 and a 200-day simple moving average of $2.51. Cellectis has a 1-year low of $0.96 and a 1-year high of $3.77. The firm has a market cap of $147.84 million, a price-to-earnings ratio of -1.59 and a beta of 3.12.

About Cellectis

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Recommended Stories

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.